Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge, with its stock price soaring 38.56%.
The dramatic move follows reports that Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on the Hims & Hers telehealth platform. This new partnership brings an end to a dispute between the two companies that had escalated into a legal battle last month, removing a significant overhang and opening a substantial new revenue channel for the telehealth provider.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.